Celularity Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celularity Inc. on January 24, 2025, regarding events occurring on January 23, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Florham Park, New Jersey. Its Class A Common Stock (CELU) and Warrants (CELUW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on the termination of a specific financing agreement.
Material Changes
The primary material event reported is the termination of a Material Definitive Agreement. On January 3, 2025, the Company entered into a securities purchase agreement for a private placement of 1,263,157 shares of Class A Common Stock and accompanying warrants at a price of $2.375 per share. On January 23, 2025, the Company notified the institutional investor that the agreement had expired due to the non-receipt of the subscription amount. Consequently, the private placement will not be consummated.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate failure to secure the previously announced capital raise. The termination of the agreement represents a contingency where expected capital inflow did not materialize.
Key Facts for Investor Verification
- The private placement of 1,263,157 shares and warrants announced on January 3, 2025, has been terminated.
- The termination was triggered by the failure of the purchaser to provide the subscription amount by the deadline.
- The Company will not receive the anticipated proceeds from this specific transaction.
- Investors should verify the Company's current cash position and alternative funding strategies given the failure of this capital raise.